JP2016513656A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513656A5
JP2016513656A5 JP2016502156A JP2016502156A JP2016513656A5 JP 2016513656 A5 JP2016513656 A5 JP 2016513656A5 JP 2016502156 A JP2016502156 A JP 2016502156A JP 2016502156 A JP2016502156 A JP 2016502156A JP 2016513656 A5 JP2016513656 A5 JP 2016513656A5
Authority
JP
Japan
Prior art keywords
substituted
heterocycle
alkyl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502156A
Other languages
English (en)
Japanese (ja)
Other versions
JP6378308B2 (ja
JP2016513656A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026498 external-priority patent/WO2014160401A1/en
Publication of JP2016513656A publication Critical patent/JP2016513656A/ja
Publication of JP2016513656A5 publication Critical patent/JP2016513656A5/ja
Application granted granted Critical
Publication of JP6378308B2 publication Critical patent/JP6378308B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502156A 2013-03-13 2014-03-13 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体 Expired - Fee Related JP6378308B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780263P 2013-03-13 2013-03-13
US201361780248P 2013-03-13 2013-03-13
US61/780,248 2013-03-13
US61/780,263 2013-03-13
PCT/US2014/026498 WO2014160401A1 (en) 2013-03-13 2014-03-13 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018129002A Division JP2018168187A (ja) 2013-03-13 2018-07-06 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体

Publications (3)

Publication Number Publication Date
JP2016513656A JP2016513656A (ja) 2016-05-16
JP2016513656A5 true JP2016513656A5 (https=) 2017-04-20
JP6378308B2 JP6378308B2 (ja) 2018-08-22

Family

ID=50639949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502156A Expired - Fee Related JP6378308B2 (ja) 2013-03-13 2014-03-13 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体
JP2018129002A Pending JP2018168187A (ja) 2013-03-13 2018-07-06 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018129002A Pending JP2018168187A (ja) 2013-03-13 2018-07-06 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体

Country Status (14)

Country Link
US (2) US20160031888A1 (https=)
EP (1) EP2970206A1 (https=)
JP (2) JP6378308B2 (https=)
KR (1) KR20150127249A (https=)
CN (1) CN105408320B (https=)
AU (2) AU2014243869A1 (https=)
BR (1) BR112015022431A2 (https=)
CA (1) CA2904152A1 (https=)
HK (1) HK1220184A1 (https=)
IL (1) IL240960A0 (https=)
MX (1) MX2015011456A (https=)
RU (2) RU2015143526A (https=)
SG (2) SG10201806965XA (https=)
WO (1) WO2014160401A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法
US10377749B2 (en) 2015-08-10 2019-08-13 Sumitomo Dainippon Pharma Co., Ltd. Purification method for 5-(thiazol-4-yl)indolin-2-one derivative
EP3363799A4 (en) * 2015-11-12 2018-12-05 LG Chem, Ltd. Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
CN105461705B (zh) * 2015-11-30 2018-04-10 中国医科大学 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法
JP2019519573A (ja) 2016-06-28 2019-07-11 ボストン バイオメディカル, インコーポレイテッド がんを処置するための方法
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN106432228A (zh) * 2016-09-06 2017-02-22 浙江司太立制药股份有限公司 含有4‑肟基‑1‑哌啶基片段的7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法
CN106397436A (zh) * 2016-09-06 2017-02-15 浙江司太立制药股份有限公司 5‑溴‑7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2019002889A1 (en) * 2017-06-30 2019-01-03 Industrial Technology Research Institute METHOD FOR TREATING AUTOIMMUNE NEUROLOGICAL DISEASE AND / OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULAS FOR LIQUID GALENIC FORM AND CONTROLLED RELEASE GALENIC FORM
CN110357878B (zh) * 2018-03-26 2022-04-12 武汉誉祥医药科技有限公司 1,3-二氢-2H-吡咯并[3,2-b]吡啶-2-酮衍生物及其医药用途
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
CN117224541A (zh) * 2018-09-18 2023-12-15 北京强新生物科技有限公司 肥胖症的治疗
MX2021003156A (es) * 2018-09-18 2021-05-14 1 Globe Biomedical Co Ltd Tratamiento para la enfermedad del higado graso no alcoholico.
US12435059B2 (en) * 2019-07-03 2025-10-07 The Regents Of The University Of Colorado, A Body Corporate AMP-activated protein kinase inhibitors and methods of making and using the same
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
WO2021243040A2 (en) * 2020-05-29 2021-12-02 The Regents Of The University Of Michigan Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof
CN111675647B (zh) * 2020-06-26 2022-03-01 深圳技术大学 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用
EP4178958A4 (en) * 2020-07-10 2024-12-11 Blossomhill Therapeutics, Inc. MACROCYCLES AND THEIR USE
AU2023204770A1 (en) * 2022-01-05 2024-07-18 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as kinase inhibitors
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途
CN117624014A (zh) * 2022-11-02 2024-03-01 徐诺药业(南京)有限公司 3-(吲哚氨基)亚甲基吲哚啉类衍生物及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (https=) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
AU7284096A (en) * 1995-10-09 1997-04-30 Dieter Binder Heterocyclically-substituted 1-indole carboxamides as cyclo-oxygenase-2 inhibitors
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1149093A1 (en) * 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
JP2004502686A (ja) * 2000-06-30 2004-01-29 スージェン・インコーポレーテッド 4−ヘテロアリール−3−ヘテロアリーリデニル−2−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
EP1349852A2 (en) * 2000-12-20 2003-10-08 Sugen, Inc. 4-(hetero)aryl substituted indolinones
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
JP2007509173A (ja) * 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
JP2008524165A (ja) * 2004-12-17 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インドリノン及びその抗増殖薬としての使用
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
CA2616383C (en) 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
MY149143A (en) * 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途
WO2008045627A2 (en) * 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
EP3037419B1 (en) * 2007-09-06 2019-09-04 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
NZ590560A (en) * 2008-07-29 2012-12-21 Boehringer Ingelheim Int Indolinone Inhibitors of cell cycle kinases
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9227962B2 (en) * 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
RU2016128396A (ru) * 2014-01-27 2018-03-02 Бостон Биомедикал, Инк. Новые способы лечения рака

Similar Documents

Publication Publication Date Title
JP6378308B2 (ja) がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体
JP2016513656A5 (https=)
CA2633023C (en) Polycyclic indazole derivatives that are erk inhibitors
CN114269735A (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
EP4351558A1 (en) Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
CN101848908A (zh) 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
US20190241550A1 (en) Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
CN110156656B (zh) 五元杂芳环衍生物、其制备方法、药物组合物及应用
AU2021410926A1 (en) Tetrahydrothienopyrimidinesulfonamide compounds
CA3167785A1 (en) Heterocyclic compounds for modulating nr2f6
EP4602043A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
JP2024508769A (ja) Wee-1阻害剤としてのピリミジン化合物
CN113880833A (zh) 联苯多环类衍生物抑制剂、其制备方法和应用
RU2802283C2 (ru) Новый ингибитор на основе производного хинолина
CN120858099A (zh) Cdk抑制剂
HK1187606B (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
HK1187606A1 (zh) 取代的6,6-稠合含氮杂环化合物及其用途
HK1139663A (en) Thiazoles and pyrazoles useful as kinase inhibitors
HK1122558A (en) Benzimidazoles useful as inhibitors of protein kinases
HK1148529B (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases